89 results on '"Böcher, W."'
Search Results
2. ITPA gene variants predict hemolytic ribavirin induced anaemia in patients treated with the interferon-free regimen of faldaprevir, BI 207127 and ribavirin in sound-C2
3. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection
4. Hepatitis B surface antigen presentation and HLA-DRB1* – lessons from twins and peptide binding studies
5. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B – restoration by exogenous interleukin-12
6. How long to treat chronic hepatitis B virus infection with lamivudine?
7. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo
8. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection†
9. WP1/008 QUANTIFICATION OF THE NEUTRALIZING HUMORAL IMMUNE RESPONSE IN PATIENTS WITH SELF-LIMITED OR PERSISTENT HBV INFECTION.
10. Biologisch-psychologische Voraussetzungen der Verkehrsteilnahme
11. Verkehrsmedizin und Psychologie
12. Hautknoten und Ulzera der Extremitäten bei einem Patienten mit rheumatoider Arthritis
13. P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVR
14. P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS
15. P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL
16. P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES
17. P1122 COMPARISONS OF POPULATIONS IN FALDAPREVIR PHASE III STUDIES BASED ON PEGYLATED INTERFERON a-2a AND RIBAVIRIN-PREDICTED RESPONSIVENESS AND IMPACT ON ACHIEVING SVR12
18. O12 RESTORATION OF HCV-SPECIFIC CD8+ T-CELL RESPONSES WITH INTERFERON-FREE TREATMENT OF HEPATITIS C
19. P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS
20. 66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R
21. 60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
22. 1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV
23. 1249 BI201335 PHARMACOKINETICS AND EARLY EFFECT ON VIRAL LOAD IN HCV GENOTYPE-1 PATIENTS
24. Combination therapy with Adefovir and Entecavir is well tolerated and effective in Lamivudine-resistant chronic Hepatitis B
25. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection
26. Daily consensus interferon versus peg-interferon alfa2b with weight based ribavirin in treatment-naive patients with chronic hepatitis C serotype-1
27. Longterm treatment with pegylated interferon-alfa2b reduces hepatocellular carcinoma incidence and prevents clinical complication in hepatitis C liver cirrhosis–an interim analysis of a multicenter trial
28. Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study
29. Eine tägliche Gabe von Interferon alpha erhöht die virale und die zusätzliche ic. aktive Impfung die biochemische Ansprechrate bei Hepatitis B
30. Bei Hepatitis B erhöht die tägliche Gabe von Interferon alpha die virale und die zusätzliche ic. HBs-Ag Impfung die biochemische Ansprechrate
31. Hautknoten und Ulzera der Extremitäten bei einem Patienten mit rheumatoider Arthritis
32. The Trimera Mouse Model of HBV and HCV Infection.
33. Untersuchungen zur Frage der Beeinflussung der Fahrtauglichkeit durch tägliche Einnahme von 3×1 Dragée Vesalium.
34. Acute cellular rejection of human renal tissue by adoptive transfer of allogeneic human peripheral blood mononuclear cells into chimeric rats: sequential gene expression of cytokines, chemokines and cytolytic effector molecules, and their regulation by CTLA-4-Ig.
35. Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
36. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
37. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
38. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
39. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
40. [Skin nodules and ulcers of the limbs in a patient with rheumatoid arthritis].
41. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.
42. In vivo modulation of the allogeneic immune response by human fetal kidneys: the role of cytokines, chemokines, and cytolytic effector molecules.
43. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.
44. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse.
45. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
46. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis.
47. Hepatic manifestation of hemolytic uremic syndrome in an allogeneic bone marrow transplant recipient.
48. [Human behavior between instinct, feelings and responsibility].
49. Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma.
50. Interstitial alveolitis as early manifestation of anti-Jo-1 positive polymyositis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.